

Anthem Pharmacy Report January – August 2014

The following graphics provide a visual aggregate reporting of the most recent 8 months reporting period (January – August 2014) as a baseline for subsequent quarterly reporting of data. Table 1 describes total number of prescriptions dispensed categorized as new, refills and non-preferred drug list (PDL). Non-PDL drugs are those that require prior authorization (PA) or have other restrictions applied and the total non-PDL drugs appear negligible vs total prescriptions dispensed. Table 2 shows the relationship between PAs requested, non-PDL prescriptions and non-PDL psych drugs as a percentage of the total number of prescriptions dispensed (new plus refills). Non-PDL psych drugs track closely with the percentage of PAs requested and Table 3 (Top 50 Non-PDL drug categories as percentage of reimbursement) shows that Solvadi accounts for 50% of non-PDL drugs as percentage of reimbursement. Insulin formulations account for 5.5% which is small but both available immediate acting insulin are non-PDL (Novolog and Humalog). Table 4 describes the number of PAs requested vs. the number of PAs denied and Table 5 shows the percentage of PAs denied with the range being generally less than 30%.

Analysis and Recommendations: Restrictions on drug accessibility appears minimal however, restrictions on the only two immediate acting insulin available on the market (Novolog and Humalog) may adversely impact members. Evaluation of impact on members is recommended.

Table 1




Table 2




Table 3




Table 4





Table 5



Coventry Pharmacy Quarterly Report 2nd Quarter 2014

The following graphics provide a visual aggregate reporting of the most recent quarter. Table 1 describes total number of prescriptions dispensed categorized as new, refills and non-preferred drug list (PDL). Non-PDL drugs are those that require prior authorization (PA) or have other restrictions applied and the total non-PDL drugs appear negligible vs total prescriptions dispensed. Table 2 shows the relationship between PAs requested, non-PDL prescriptions and non-PDL psych drugs as a percentage of the total number of prescriptions dispensed (new plus refills). Non-PDL psych drugs track closely with the percentage of PAs requested and Table 3 (Top 50 Non-PDL drug categories) shows that antipsychotics and ADHD drugs account for 60% of non-PDL drugs by reimbursement, an increase from March 2013-March 2014 rate of 44%. Table 4 describes the number of PAs requested vs. the number of PAs denied and Table 5 shows the percentage of PAs denied with the range being generally less than 30%.

Analysis and Recommendations: Restrictions on drug accessibility appears to have increased during quarter 2 vs. last year. Will track and trend quarterly going forward.

Table 1




Table 2




Table 3




Table 4





Table 5



Coventry Pharmacy Quarterly Report 3rd Quarter 2014

The following graphics provide a visual aggregate reporting of the most recent quarter. Table 1 describes total number of prescriptions dispensed categorized as new, refills and non-preferred drug list (PDL). Non-PDL drugs are those that require prior authorization (PA) or have other restrictions applied and the total non-PDL drugs appear negligible vs total prescriptions dispensed. Table 2 shows the relationship between PAs requested, non-PDL prescriptions and non-PDL psych drugs as a percentage of the total number of prescriptions dispensed (new plus refills). Non-PDL psych drugs track closely with the percentage of PAs requested and Table 3 (Top 50 Non-PDL drug categories) shows that Solvadi and other specialty drugs account for 60% of non-PDL drugs by percentage of reimbursement, a change from the previous quarter where antipsychotics and ADHD drugs contributed to 60% of the top 50 drugs by reimbursement. Table 4 describes the number of PAs requested vs. the number of PAs denied and Table 5 shows the percentage of PAs denied with the range being generally less than 30%.

Analysis and Recommendations: Drug restrictions appear to have focused on Solvadi and other specialty drugs, closely followed by antipsychotics.

Table 1




Table 2




Table 3




Table 4





Table 5



Humana Pharmacy Quarterly Report

The following graphics provide a visual aggregate reporting of the most recent quarter data. Table 1 describes total number of prescriptions dispensed categorized as new, refills and. Non-PDL drugs are those that require prior authorization (PA) or have other restrictions applied and the total non-PDL drugs are negligible vs total prescriptions dispensed. Table 2 shows the relationship between PAs requested and non-PDL prescriptions as a percentage of the total number of prescriptions dispensed (new plus refills) which are both very low at less than 1.2%, a decrease from last quarter which was less than 2.5%. Table 3 describes the number of PAs requested vs. the number of PAs denied and Table 4 shows the percentage of PAs denied with the range being between 30-40% since October 2013.

Analysis and Recommendations: Restrictions on drug accessibility appears minimal. No recommendations at this time.

Table 1




Table 2




Table 3





Table 4



Humana Pharmacy Report 3rd Quarter 2014

The following graphics provide a visual aggregate reporting of the most recent quarter data. Table 1 describes the total number of prescriptions dispensed categorized as new, refills, and non-PDL drugs. Non-PDL drugs are those that require prior authorization (PA) or have other restrictions applied and the total non-PDL drugs are negligible vs total prescriptions dispensed. The relationship between PAs requested and non-PDL prescriptions as a percentage of the total number of prescriptions dispensed (new plus refills) are both very low at less than one percent, therefore graphical analysis is not reported. The Top 50 Non-PDL Drug by Reimbursement report number 45b showed that the majority of non-PDL drugs were vaccines (Zostrix, Pneumococcal and influenza), therefore graphical analysis is not reported. Table 2 describes the number of PAs requested vs. the number of PAs denied and Table 3 shows the percentage of PAs denied with the range being between 30-40% since October 2013.

Analysis and Recommendations: Restrictions on drug accessibility appears minimal. No recommendations at this time.

Table 1




Table 2





Table 3



Passport Pharmacy Quarterly Report

The following graphics provide a visual aggregate reporting of the most recent quarterly reporting of data. Table 1 describes total number of prescriptions dispensed categorized as new, refills and non-preferred drug list (PDL). Non-PDL drugs are those that require prior authorization (PA) or have other restrictions applied and the total non-PDL drugs appear negligible vs total prescriptions dispensed. Table 2 shows the relationship between PAs requested and non-PDL prescriptions as a percentage of the total number of prescriptions dispensed (new plus refills) which are both very low at less than 2.0% which remains steady vs. last quarter. Table 3 describes the number of PAs requested vs. the number of PAs denied and Table 4 shows the percentage of PAs denied with the range being generally less than 25%. Table 5, the Top 50 Non-PDL drug categories by claim count shows that addiction therapy (Suboxone), ADHD, and specialty drugs account for more than 70% of non-PDL drugs by claims.

Analysis and Recommendations: Restrictions on drug accessibility appears minimal. No recommendations at this time.

Table 1




Table 2




Table 3




Table 4





Table 5



Passport Pharmacy Report 3rd Quarter 2014

The following graphics provide a visual aggregate reporting of the most recent quarterly reporting of data. Table 1 describes total number of prescriptions dispensed categorized as new, refills and non-preferred drug list (PDL). Non-PDL drugs are those that require prior authorization (PA) or have other restrictions applied and the total non-PDL drugs appear negligible vs total prescriptions dispensed. Table 2 shows the relationship between PAs requested and non-PDL prescriptions as a percentage of the total number of prescriptions dispensed (new plus refills) which are both very low at less than 1.5% which remains steady vs. last quarter. Table 3 describes the number of PAs requested vs. the number of PAs denied and Table 4 shows the percentage of PAs denied with the range trending back down to the 25% range from a high of above 40% (July). Table 5, the Top 50 Non-PDL drug categories by claim count shows that addiction therapy (Suboxone), ADHD, and specialty drugs account for more than 70% of non-PDL drugs by claims which are similar to last quarter.

Analysis and Recommendations: Restrictions on drug accessibility appears minimal. No recommendations at this time.

Table 1




Table 2




Table 3




Table 4





Table 5



WellCare Pharmacy Quarterly Report

The following graphics provide a visual aggregate reporting of the most recent quarterly reporting of data. Table 1 describes total number of prescriptions dispensed categorized as new, refills and non-preferred drug list (PDL). Non-PDL drugs are those that require prior authorization (PA) or have other restrictions applied and the total non-PDL drugs appear negligible and consistent vs. prior quarter. Table 2 shows the relationship between PAs requested, non-PDL prescriptions and non-PDL psych drugs as a percentage of the total number of prescriptions dispensed (new plus refills). Non-PDL psych drugs track closely with the percentage of PAs requested and Table 3 (Top 50 Non-PDL drug categories) shows that insulin formulations (LANTUS SOLOSTAR 100 UNITS/ML, HUMALOG 100 UNITS/ML KWIKPEN, NOVOLOG 100 UNIT/ML VIAL, LEVEMIR 100 UNITS/ML VIAL, LEVEMIR FLEXPEN 100 UNITS/ML, NOVOLOG FLEXPEN SYRINGE, HUMALOG MIX 75-25 KWIKPEN, NOVOLOG MIX 70-30 VIAL) and psych/pain medications (generic duloxetine and Lyrica) account for 69% of non-PDL drugs by rx count. Table 4 describes the number of PAs requested vs. the number of PAs denied and Table 5 shows the percentage of PAs denied with the range being between 50-57% since October 2013.

Analysis and Recommendation: WellCare displays the highest rate of PAs denied compared to all other KY MCO Pharmacy Benefit Plans – see Table 6. Also, restriction and potential delay of access to insulin products may result in adverse member outcomes due to the broad range of products identified. Evaluation of impact on members is recommended.

Table 1




Table 2




Table 3




Table 4




Table 5





Table 6



* Average of 12 months of data: Mar 2013-Mar 2014 for Coventry and Passport and Apr 2013-Apr 2014 for Humana and WellCare